A patient with advanced cholangiocarcinoma (CCA) successively received EGFR and CD133 CAR‐T cells therapy and showed a partial response (PR) continuously, which proved the feasibility of the cocktail immunotherapy [65]. The gene discussed is EGFR; the disease is cholangiocarcinoma.